Sandro P.
- Country
- Italy
- Department
- Urology and Gynecology
Research Overview
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- Phase 3 Randomized Study of Pembrolizumab Versus Platinum-Based Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma
Data & Insights
Has run more than one trial at 198 of 411 partner sites.
Specializations
Gynecologic Oncology
Specializes in treating ovarian cancer, fallopian tube cancer, and peritoneal cancer with targeted maintenance therapies. Conducts research on both BRCA wild-type and BRCA-mutated variants.
- Epithelial ovarian tumors
- Endometrial carcinoma
- Cervical cancer
Explores biomarker-driven approaches and combination treatments with novel therapeutic agents.
Urologic Oncology
Focuses on advanced treatments for metastatic prostate cancer, including both castration-resistant and castration-sensitive variants. Investigates novel therapeutic combinations.
- Prostate cancer therapeutics
- Renal cell carcinoma
- DDR gene mutations
Specializes in targeted therapies and immunotherapy approaches for urological malignancies.
Precision Medicine
Implements biomarker-driven treatment strategies across multiple cancer types. Focuses on homologous recombination deficiency and targeted therapeutics.
- Molecular profiling
- Targeted therapy combinations
- Immunotherapy applications
Develops personalized treatment approaches based on molecular and genetic characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.